Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Efavirenz

FDA-approved product (capsule, oral), marketed as Efavirenz, Sustiva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Efavirenz
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Efavirenz in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Efavirenz with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Disulfiram Interactions With HIV Medications: Clinical Implications

    NCT00878306 · start 2008-11

    Registered record
    Registry ID
    NCT00878306
    Conditions
    HIV Infections; Drug Abuse
    Interventions
    Disulfiram; Disulfiram + Efavirenz; Disulfiram + Atazanavir; Disulfiram + Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-11
    Completion
    2013-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Drug Abuse
    InterventionDisulfiram; Disulfiram + Efavirenz; Disulfiram + Atazanavir; Disulfiram + Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment

    NCT00737724 · start 2008-03

    Registered record
    Registry ID
    NCT00737724
    Conditions
    HIV; AIDS; Tuberculosis
    Interventions
    Simultaneous ARV and antiMTB; Deferred RV and antiMTB treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2008-03
    Completion
    2011-02
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS; Tuberculosis
    InterventionSimultaneous ARV and antiMTB; Deferred RV and antiMTB treatment
    PhaseNot applicable
    Registry statusTerminated

  • Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men

    NCT00846599 · start 2008-01

    Registered record
    Registry ID
    NCT00846599
    Conditions
    HIV Infection; Cardiovascular Risk; HIV Infections
    Interventions
    Omega-3 study meal; Saturated fat study meal
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-01
    Completion
    2010-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Cardiovascular Risk; HIV Infections
    InterventionOmega-3 study meal; Saturated fat study meal
    PhaseNot recorded
    Registry statusCompleted

  • KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects

    NCT00549198 · start 2007-06

    Registered record
    Registry ID
    NCT00549198
    Conditions
    Infection, Human Immunodeficiency Virus I; HIV Infection
    Interventions
    Abacavir/lamivudine and efavirenz; Tenofovir/Emtricitabine and efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-06
    Completion
    2009-12
    Enrolment
    392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus I; HIV Infection
    InterventionAbacavir/lamivudine and efavirenz; Tenofovir/Emtricitabine and efavirenz
    PhasePhase 4
    Registry statusCompleted

  • ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

    NCT00335322 · start 2007-02

    Registered record
    Registry ID
    NCT00335322
    Conditions
    Human Immunodeficiency Virus (HIV)
    Interventions
    Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-02
    Completion
    2011-11
    Enrolment
    329

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV)
    InterventionTruvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    PhasePhase 4
    Registry statusCompleted

  • Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children

    NCT00364793 · start 2007-02

    Registered record
    Registry ID
    NCT00364793
    Conditions
    HIV Infections
    Interventions
    Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2013-07
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEfavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment

    NCT00332306 · start 2006-06

    Registered record
    Registry ID
    NCT00332306
    Conditions
    Tuberculosis; Human Immunodeficiency Virus Infections
    Interventions
    Didanosine, Lamivudine, Efavirenz; Didanosine, Lamivudine, Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-06
    Completion
    2011-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus Infections
    InterventionDidanosine, Lamivudine, Efavirenz; Didanosine, Lamivudine, Nevirapine
    PhasePhase 3
    Registry statusUnknown

  • Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage

    NCT00556634 · start 2006-04

    Registered record
    Registry ID
    NCT00556634
    Conditions
    HIV-1 Infection; HIV Infection
    Interventions
    Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-04
    Completion
    2008-01
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection; HIV Infection
    InterventionEfavirenz
    PhasePhase 4
    Registry statusCompleted

  • A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

    NCT00110305 · start 2005-06

    Registered record
    Registry ID
    NCT00110305
    Conditions
    Human Immunodeficiency Virus Type 1
    Interventions
    TMC278 25 mg; TMC278 75 mg; TMC278 150 mg; Efavirenz; Non-nucleoside reverse transcriptase inhibitor (NRTIs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-06
    Completion
    2011-12
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Type 1
    InterventionTMC278 25 mg; TMC278 75 mg; TMC278 150 mg; Efavirenz +1 more
    PhasePhase 2
    Registry statusCompleted

  • Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

    NCT00098293 · start 2004-11

    Registered record
    Registry ID
    NCT00098293
    Conditions
    HIV-1
    Interventions
    Maraviroc + Zidovudine/Lamivudine; Efavirenz + Zidovudine/Lamivudine; Maraviroc (UK-427,857) + Zidovudine/Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-11
    Completion
    2012-12
    Enrolment
    916

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionMaraviroc + Zidovudine/Lamivudine; Efavirenz + Zidovudine/Lamivudine; Maraviroc (UK-427,857) + Zidovudine/Lamivudine
    PhasePhase 3
    Registry statusCompleted

  • A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

    NCT00135343 · start 2004-04

    Registered record
    Registry ID
    NCT00135343
    Conditions
    HIV Infections
    Interventions
    Atazanvir/ritonavir + efavirenz; Atazanvir/ritonavir + efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-04
    Completion
    2005-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanvir/ritonavir + efavirenz; Atazanvir/ritonavir + efavirenz
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients

    NCT00318123 · start 2004-04

    Registered record
    Registry ID
    NCT00318123
    Conditions
    HIV Infections
    Interventions
    Kivexa
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-04
    Completion
    2007-04
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionKivexa
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

    NCT00158405 · start 2002-12

    Registered record
    Registry ID
    NCT00158405
    Conditions
    HIV Infections
    Interventions
    Structured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV); Ritonavir (NRV); Indinavir (IDV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-12
    Completion
    2006-12
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionStructured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV) +2 more
    PhasePhase 3
    Registry statusCompleted

  • An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

    NCT00162188 · start 2001-05

    Registered record
    Registry ID
    NCT00162188
    Conditions
    HIV Infection
    Interventions
    Efavirenz
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    2001-05
    Completion
    2010-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionEfavirenz
    PhaseNot recorded
    Registry statusNo longer available